Cotreatment with Aspirin and Azole Drugs Increases Sensitivity of Candida albicans in vitro

References

• von Lilienfeld-toal M, Wagener J, Einsele H, Cornely OA, Kurzai O. Invasive fungal infection. Dtsch Arztebl Int. 2019;116(16):271–278. doi:10.3238/arztebl.2019.027131159914
   PubMed Web of Science ®Google Scholar
• Gajdacs M, Doczi I, Abrok M, Lazar A, Burian K. Epidemiology of candiduria and Candida urinary tract infections in inpatients and outpatients: results from a 10-year retrospective survey. Cent European J Urol. 2019;72(2):209–214. doi:10.5173/ceju.2019.1909
   PubMed Web of Science ®Google Scholar
• Fu J, Ding Y, Wei B, et al. Epidemiology of Candida albicans and non-C.albicans of neonatal candidemia at a tertiary care hospital in western China. BMC Infect Dis. 2017;17(1):329. doi:10.1186/s12879-017-2423-828477628
   PubMed Web of Science ®Google Scholar
• Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20(Suppl 6):5–10. doi:10.1111/1469-0691.12539
   Web of Science ®Google Scholar
• Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73(suppl_1):i4–i13. doi:10.1093/jac/dkx44429304207
   PubMed Web of Science ®Google Scholar
• Hani U, Shivakumar HG, Vaghela R, Osmani RA, Shrivastava A. Candidiasis: a fungal infection–current challenges and progress in prevention and treatment. Infect Disord Drug Targets. 2015;15(1):42–52. doi:10.2174/187152651566615032016203625809621
   PubMedGoogle Scholar
• Katragkou A, McCarthy M, Alexander EL, et al. In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. J Antimicrob Chemother. 2015;70(2):470–478. doi:10.1093/jac/dku37425288679
   PubMed Web of Science ®Google Scholar
• Golabek K, Strzelczyk JK, Owczarek A, Cuber P, Slemp-Migiel A, Wiczkowski A. Selected mechanisms of molecular resistance of Candida albicans to azole drugs. Acta Biochim Pol. 2015;62(2):247–251. doi:10.18388/abp.2014_94025901298
   PubMed Web of Science ®Google Scholar
• Akbari F, Kjellerup BV. Elimination of bloodstream infections associated with Candida albicans biofilm in intravascular catheters. Pathogens. 2015;4(3):457–469. doi:10.3390/pathogens403045726131615
   PubMedGoogle Scholar
• Kim DJ, Lee MW, Choi JS, Lee SG, Park JY, Kim SW. Inhibitory activity of hinokitiol against biofilm formation in fluconazole-resistant Candida species. PLoS One. 2017;12(2):e0171244. doi:10.1371/journal.pone.017124428152096
   PubMed Web of Science ®Google Scholar
• Noverr MC, Phare SM, Toews GB, Coffey MJ, Huffnagle GB, Kozel TR. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect Immun. 2001;69(5):2957–2963. doi:10.1128/IAI.69.5.2957-2963.200111292712
   PubMed Web of Science ®Google Scholar
• Deva R, Ciccoli R, Kock L, Nigam S. Involvement of aspirin-sensitive oxylipins in vulvovaginal candidiasis. FEMS Microbiol Lett. 2001;198(1):37–43. doi:10.1111/j.1574-6968.2001.tb10616.x11325551
   PubMed Web of Science ®Google Scholar
• Madariaga-Venegas F, Fernandez-Soto R, Duarte LF, et al. Characterization of a novel antibiofilm effect of nitric oxide-releasing aspirin (NCX-4040) on Candida albicans isolates from denture stomatitis patients. PLoS One. 2017;12(5):e0176755. doi:10.1371/journal.pone.017675528493889
   PubMed Web of Science ®Google Scholar
• Rusu E, Radu-Popescu M, Pelinescu D, Vassu T. Treatment with some anti-inflammatory drugs reduces germ tube formation in Candida albicans strains. Braz J Microbiol. 2014;45(4):1379–1383. doi:10.1590/s1517-8382201400040003125763044
   PubMed Web of Science ®Google Scholar
• Ogundeji AO, Pohl CH, Sebolai OM. Repurposing of aspirin and ibuprofen as candidate anti-cryptococcus drugs. Antimicrob Agents Chemother. 2016;60(8):4799–4808. doi:10.1128/AAC.02810-1527246782
   PubMed Web of Science ®Google Scholar
• Silva NC, JsM N, Dias ALT. Aspartic proteinases of Candida spp.: role in pathogenicity and antifungal resistance. Mycoses. 2013;57(1):1–11. doi:10.1111/myc.1209523735296
   PubMed Web of Science ®Google Scholar
• Chen S, Xia J, Li C, Zuo L, Wei X. The possible molecular mechanisms of farnesol on the antifungal resistance of C. albicans biofilms: the regulation of CYR1 and PDE2. BMC Microbiol. 2018;18(1):203. doi:10.1186/s12866-018-1344-z30509171
   PubMed Web of Science ®Google Scholar
• Hawser SP, Baillie GS, Douglas LJ. Production of extracellular matrix by Candida albicans biofilms. J Med Microbiol. 1998;47(3):253–256. doi:10.1099/00222615-47-3-2539511830
   PubMed Web of Science ®Google Scholar
• Feng W, Yang J, Yang L, et al. Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications. Exp Ther Med. 2018;15(2):1217–1224. doi:10.3892/etm.2017.551829434708
   PubMed Web of Science ®Google Scholar
• Feng W, Yang J, Ji Y, et al. Mrr2 mutations and upregulation are associated with increased fluconazole resistance in Candida albicans isolates from patients with vulvovaginal candidiasis. Lett Appl Microbiol. 2020;70(2):95–101. doi:10.1111/lam.1324831705810
   PubMed Web of Science ®Google Scholar
• Shi C, Liu J, Li W, Zhao Y, Meng L, Xiang M. Expression of fluconazole resistance-associated genes in biofilm from 23 clinical isolates of Candida albicans. Braz J Microbiol. 2019;50(1):157–163. doi:10.1007/s42770-018-0009-230617866
   PubMed Web of Science ®Google Scholar
• Tamura T, Asahara M, Yamamoto M, et al. In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes. Microbiol Immunol. 2014;58(1):1–8. doi:10.1111/1348-0421.1210924215461
   PubMed Web of Science ®Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. doi:10.1093/jac/dkg30112805255
   PubMed Web of Science ®Google Scholar
• Feng W, Yang J, Ma Y, et al. Aspirin and verapamil increase the sensitivity of Candida albicans to caspofungin under planktonic and biofilm conditions. J Glob Antimicrob Resist. 2021;24:32–39. doi:10.1016/j.jgar.2020.11.01333242673
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin H, Liu W, et al. Antifungal activity of the ethanol extract from flos rosae chinensis with activity against fluconazole-resistant clinical Candida. Evid Based Complement Alternat Med. 2017;2017:4780746. doi:10.1155/2017/478074628303159
   PubMed Web of Science ®Google Scholar
• Ahangarkani F, Khodavaisy S, Mahmoudi S, et al. Indifferent effect of nonsteroidal anti-inflammatory drugs (NSAIDs) combined with fluconazole against multidrug-resistant Candida auris. Curr Med Mycol. 2019;5(3):26–30. doi:10.18502/cmm.5.3.1743
   Google Scholar
• Krol J, Nawrot U, Bartoszewicz M. Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole. J Mycol Med. 2018;28(2):327–331. doi:10.1016/j.mycmed.2018.03.00229605543
   PubMed Web of Science ®Google Scholar
• Pina-Vaz C, Sansonetty F, Rodrigues AG, Martinez DEOJ, Fonseca AF, Mardh PA. Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J Med Microbiol. 2000;49(9):831–840. doi:10.1099/0022-1317-49-9-83110966233
   PubMed Web of Science ®Google Scholar
• Scott EM, Tariq VN, McCrory RM. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob Agents Chemother. 1995;39(12):2610–2614. doi:10.1128/aac.39.12.26108592988
   PubMed Web of Science ®Google Scholar
• Mitchell KF, Zarnowski R, Sanchez H, et al. Community participation in biofilm matrix assembly and function. Proc Natl Acad Sci U S A. 2015;112(13):4092–4097. doi:10.1073/pnas.142143711225770218
   PubMed Web of Science ®Google Scholar
• Blankenship JR, Mitchell AP. How to build a biofilm: a fungal perspective. Curr Opin Microbiol. 2006;9(6):588–594. doi:10.1016/j.mib.2006.10.00317055772
   PubMed Web of Science ®Google Scholar
• Tan Y, Leonhard M, Ma S, Schneider-Stickler B. Influence of culture conditions for clinically isolated non-albicans Candida biofilm formation. J Microbiol Methods. 2016;130:123–128. doi:10.1016/j.mimet.2016.09.01127647064
   PubMed Web of Science ®Google Scholar
• Senobar Tahaei SA, Stájer A, Barrak I, Ostorházi E, Szabó D, Gajdács M. Correlation between biofilm-formation and the antibiotic resistant phenotype in staphylococcus aureus isolates: a Laboratory-Based Study in Hungary and a review of the literature. Infect Drug Resist. 2021;14:1155–1168. doi:10.2147/idr.S30399233790586
   PubMed Web of Science ®Google Scholar
• Gajdacs M, Spengler G. The role of drug repurposing in the development of novel antimicrobial drugs: non-antibiotic pharmacological agents as quorum sensing-inhibitors. Antibiotics (Basel). 2019;8(4). doi:10.3390/antibiotics8040270
   Web of Science ®Google Scholar
• Alem MA, Douglas LJ. Effects of aspirin and other nonsteroidal anti-inflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob Agents Chemother. 2004;48(1):41–47. doi:10.1128/aac.48.1.41-47.200414693516
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang G, Li Y, et al. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis. Antimicrob Agents Chemother. 2012;56(6):3250–3260. doi:10.1128/AAC.06082-1122391539
   PubMed Web of Science ®Google Scholar